Research programme: RNA-based antiviral therapeutics- Sarepta Therapeutics

Drug Profile

Research programme: RNA-based antiviral therapeutics- Sarepta Therapeutics

Alternative Names: Anti-IL-10 PMO; AVI-6001; AVI-6006; AVI-7012; NeuGene antiviral antisense compounds; NP AUG PMO; PB2 AUG PMO; Viral PMO-X for dengue - Sarepta Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVI BioPharma
  • Developer Sarepta Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Genetic transcription inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dengue; HIV infections; Influenza virus infections; Junin virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Dengue in USA (Parenteral)
  • 16 Apr 2013 Research in therapies for Dengue is ongoing in USA
  • 16 Apr 2013 No development reported - Preclinical for HIV infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top